CoChat

The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

Objective: Preclinical studies, observational studies, and clinical trials suggest that thiazolidinediones (TZDs) reduce bone mineral density (BMD) and increase fracture risk. Most of the evidence on the skeletal effects of TZDs is from studies of rosiglitazone. We set out to investigate the magnitude and etiology of the adverse skeletal effects of pioglitazone. Design: Double-blind, randomized controlled trial. Trial registration: Australia New Zealand Clinical Trials Registry, actr.org.au Identifier: ACTRN12607000610437, date of registration 28/11/07. Methods: A total of 86 people with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), median age 64 years, were randomized to receive either pioglitazone 30 mg/day or placebo for 1 year, in addition to their usual diabetes treatments. The primary outcome was change in lumbar spine BMD; secondary outcomes included changes in BMD at other sites and in biochemical markers of bone turnover. Results: Change in spine BMD was not altered by treatment with pioglitazone (Ptreatment×time=0.5). After 1 year, the mean (95% CI) between-groups difference in lumbar spine BMD was −0.7% (−2.1, 0.7). Pioglitazone increased bone loss at the proximal femur (Ptreatment×time=0.03). After 12 months, the between-groups difference in total hip BMD was −1.2% (−2.1, 0.2). Pioglitazone did not alter change in BMD at other skeletal sites, nor did it affect changes in the levels of either of the biochemical markers of bone turnover, procollagen type 1 N-terminal propeptide, or β-C-terminal telopeptide of type 1 collagen. Conclusions: Over 1 year, treatment with pioglitazone 30 mg/day did not produce consistent effects on either BMD or bone turnover in people with T2DM or IGT. The mechanism(s) by which pioglitazone increases fracture risk in T2DM is unclear.

Overview

Integrity signals

Registry

Crossref · 10.1530/eje-13-0793

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 1

  1. 2007, Journal of Clinical Endocrinology & Metabolism, 298, 1180

Cited by

See all 43

Metadata

Authors
Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R.
Affiliations
University of Auckland (NZ)
Corresponding author
Grey, Andrew
Venue
European Journal of Endocrinology
Published
2014-02
Volume
170
Issue
2
Pages
255-262
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W2116755767
Cited by
43
References
32
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 7
FWCI
6.81
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords
pioglitazone, thiazolidinediones, type 2 diabetes, impaired glucose tolerance, bone mineral density, bone loss, fracture risk, bone turnover markers, lumbar spine, proximal femur, hip bone density, rosiglitazone
MeSH terms
Pioglitazone, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Lumbar Vertebrae, Male, Middle Aged, Risk, Spine, Bone Density, Bone Remodeling, Glucose Intolerance, Thiazolidinediones, Bone Density Conservation Agents, Fractures, Bone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. https://app.cochat.ai/papers/10.1530/eje-13-0793
The paper
Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R. (2014). The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. European Journal of Endocrinology. https://doi.org/10.1530/eje-13-0793

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.